A randomised, double-blind, active-controlled study to evaluate the efficacy, safety and sustainability of a comprehensive real-world digital asynchronous weight management service that combines glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment with proactive personalised guidance in nutrition, and resistance and aerobic training in adults with overweight or obesity.
100 Clinical Results associated with Hangzhou Eucalyptus Biotechnology Co., Ltd.
0 Patents (Medical) associated with Hangzhou Eucalyptus Biotechnology Co., Ltd.
100 Deals associated with Hangzhou Eucalyptus Biotechnology Co., Ltd.
100 Translational Medicine associated with Hangzhou Eucalyptus Biotechnology Co., Ltd.